Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

Recombinant human erythropoietin (rhEPO) has been saving millions of lives worldwide as a potent and safe treatment for the lack of erythrocyte, which is caused by chronic kidney disease (CKD) and other issues. Several biosimilars of rhEPO have been approved since the expiry of the relevant patents to provide cost-effective options but the price of rhEPO is still high for the affordability of global community. Therefore, development of biosimilar of rhEPO at a lower price is highly necessary. Here we report the development and characterization of a biosimilar of rhEPO with high-yield satisfying regulatory requirements. The hEPO-expressing cDNA was stably expressed in CHO cells with successive transfection. The master cell bank (MCB) and working cell bank (WCB) were established from the best selected clone and characterized for 50 passages. The rhEPO was expressed from the WCB in single-use suspension culture system with a high-titer (1.24±0.16 g/L). To the best of our knowledge this is the highest reported rhEPO titer to date. The rhEPO was purified using a series of validated chromatography unit processes including virus inactivation and filtration. The purified EPO was formulated in serum-free buffer, sterile filtered, and analyzed as the biosimilar of reference product Eprex®. Physicochemical analysis strongly suggested similarities between the developed rhEPO (GBPD002) and the reference. The in vitro and in vivo functional assays confirmed the similar biofunctionality of the GBPD002 and Eprex®. GBPD002 could provide a less-expensive solution to the needful communities as an effective and safe biosimilar where rhEPO treatment is necessary.

[1]  K. Vareesangthip,et al.  Biosimilar erythropoietin in anemia treatment (BEAT)—Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study , 2022, Medicine.

[2]  Michael C. Borys,et al.  Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning , 2022, Bioengineering.

[3]  K. M. Islam,et al.  Prevalence of Anemia in Chronic Kidney Disease , 2021 .

[4]  Joel T Welch,et al.  Considering "clonality": A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. , 2019, Biologicals : journal of the International Association of Biological Standardization.

[5]  Ivana Knezevic,et al.  Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study , 2019, Biologicals : journal of the International Association of Biological Standardization.

[6]  G. Lee,et al.  Cell Line Development for Therapeutic Protein Production , 2019, Cell Culture Engineering.

[7]  GaBI Journal Editor.  Patent expiry dates for biologicals: 2018 update , 2019, Generics and Biosimilars Initiative Journal.

[8]  S. Fishbane,et al.  Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[9]  Xiang Li,et al.  Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan , 2018, Journal of pharmaceutical and biomedical analysis.

[10]  J. Lipton,et al.  Erythropoiesis: insights into pathophysiology and treatments in 2017 , 2018, Molecular Medicine.

[11]  J. Lipton,et al.  Erythropoiesis: insights into pathophysiology and treatments in 2017 , 2018, Molecular Medicine.

[12]  F. Leisch,et al.  Changes in Chromosome Counts and Patterns in CHO Cell Lines upon Generation of Recombinant Cell Lines and Subcloning. , 2018, Biotechnology journal.

[13]  C. Pohl,et al.  High Performance Anion Exchange and Hydrophilic Interaction Liquid Chromatography Approaches for Comprehensive Mass Spectrometry-Based Characterization of the N-Glycome of a Recombinant Human Erythropoietin. , 2018, Journal of Proteome Research.

[14]  M. Aapro,et al.  Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained , 2018, BioDrugs.

[15]  M. Saugy,et al.  Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects , 2017, Molecular and Cellular Endocrinology.

[16]  Patent expiry dates for biologicals : 2017 update , 2018 .

[17]  D. Goldsmith,et al.  Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia , 2016, BMC Nephrology.

[18]  F. Reis,et al.  Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose , 2016, Clinical and experimental pharmacology & physiology.

[19]  C. Frye,et al.  Industry view on the relative importance of "clonality" of biopharmaceutical-producing cell lines. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[20]  M. Wadhwa,et al.  Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. , 2016, Journal of pharmaceutical sciences.

[21]  B. Snedecor,et al.  Slashing the timelines: Opting to generate high‐titer clonal lines faster via viability‐based single cell sorting , 2016, Biotechnology progress.

[22]  E. Lerma,et al.  Anemia of chronic kidney disease. , 2015, Disease-a-month : DM.

[23]  Jaeseung Yoon,et al.  Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study , 2015, Clinical Drug Investigation.

[24]  M. Memo,et al.  An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin , 2015, BioDrugs.

[25]  Stephan O. Krause.  PCMO L01—Setting Specifications for Biological Investigational Medicinal Products , 2015, PDA Journal of Pharmaceutical Science and Technology.

[26]  A. Racher,et al.  Diversity in host clone performance within a Chinese hamster ovary cell line , 2015, Biotechnology progress.

[27]  Antonio Santoro,et al.  Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS) , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  J. Wish.  The approval process for biosimilar erythropoiesis-stimulating agents. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[29]  M. Stauffer,et al.  Prevalence of Anemia in Chronic Kidney Disease in the United States , 2014, PloS one.

[30]  F. Wurm.  CHO Quasispecies—Implications for Manufacturing Processes , 2013 .

[31]  Edward J. O'Brien,et al.  Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome , 2013, Nature Biotechnology.

[32]  M. Wadhwa,et al.  Biosimilars: what clinicians should know. , 2012, Blood.

[33]  G. D. de Jong,et al.  Profiling of erythropoietin products by capillary electrophoresis with native fluorescence detection , 2012, Electrophoresis.

[34]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[35]  C. Reichel.  The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. , 2011, Drug testing and analysis.

[36]  Kelvin H. Lee,et al.  The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line , 2011, Nature Biotechnology.

[37]  Marité Ode,et al.  Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas , 2011, Drugs in R&D.

[38]  V. Wizemann,et al.  Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia , 2010, Advances in therapy.

[39]  T. Munro,et al.  Intraclonal Protein Expression Heterogeneity in Recombinant CHO Cells , 2009, PloS one.

[40]  M. Kinzig,et al.  Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations , 2008, Pharmacology.

[41]  Allen R Nissenson,et al.  Epoetin‐associated pure red cell aplasia: past, present, and future considerations , 2008, Transfusion.

[42]  T. Misteli,et al.  Activation of the Cellular DNA Damage Response in the Absence of DNA Lesions , 2008, Science.

[43]  I. Macdougall.  Novel erythropoiesis-stimulating agents: a new era in anemia management. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[44]  B. Enenkel,et al.  Selection of high-producing CHO cells using NPT selection marker with reduced enzyme activity. , 2005, Biotechnology and bioengineering.

[45]  M. Arcasoy,et al.  Erythropoietin and erythropoietin receptor expression in human prostate cancer , 2005, Modern Pathology.

[46]  Alan J Dickson,et al.  Stability of protein production from recombinant mammalian cells , 2003, Biotechnology and bioengineering.

[47]  V. Skibeli,et al.  Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. , 2001, Blood.

[48]  T. Arakawa,et al.  Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. , 2001, Protein engineering.

[49]  I. Wilson,et al.  Shared and Unique Determinants of the Erythropoietin (EPO) Receptor Are Important for Binding EPO and EPO Mimetic Peptide* , 1999, The Journal of Biological Chemistry.

[50]  Wen He,et al.  An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation , 1998, Nature Structural Biology.

[51]  C. Ryu,et al.  Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. , 1998, Biotechnology and bioengineering.

[52]  T. Arakawa,et al.  The effect of carbohydrate on the structure and stability of erythropoietin. , 1991, The Journal of biological chemistry.

[53]  D. Stott,et al.  Immunoblotting and dot blotting , 1989, Journal of Immunological Methods.

[54]  M. Fukuda,et al.  Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. , 1989, Blood.

[55]  Y. Kim,et al.  Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. , 1987, The Journal of biological chemistry.

[56]  Y. Assaraf,et al.  Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. , 1987, The New England journal of medicine.

[58]  T. Arakawa,et al.  Structural characterization of human erythropoietin. , 1986, The Journal of biological chemistry.

[59]  J. Egrie,et al.  Erythropoietin: gene cloning, protein structure, and biological properties. , 1986, Cold Spring Harbor symposia on quantitative biology.